Association of GLP-1 Receptor Agonists and Hepatocellular Carcinoma Incidence and Hepatic Decompensation in Patients With Type 2 Diabetes

Gastroenterology, Journal Year: 2024, Volume and Issue: 167(4), P. 689 - 703

Published: April 29, 2024

Hepatocellular carcinoma (HCC) is a leading cause of cancer death. HCC preventable with about 70% attributable to modifiable risk factors. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), Food and Drug Administration-approved medications for treating type 2 diabetes mellitus (T2DM), have pleiotropic effects on counteracting factors HCC. Here we evaluate the association GLP-1RAs incident in real-world population.

Language: Английский

---

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350

Published: April 24, 2024

BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.

Language: Английский

---

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108

Published: March 12, 2024

This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.

Language: Английский

---

The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes

Liver International, Journal Year: 2024, Volume and Issue: 44(10), P. 2538 - 2550

Published: July 1, 2024

We examined the impact of a co-diagnosis metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) on patient outcomes.

Language: Английский

---

Management of Metabolic-Associated Fatty Liver Disease/Metabolic Dysfunction-Associated Steatotic Liver Disease: From Medication Therapy to Nutritional Interventions

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2220 - 2220

Published: July 11, 2024

Non-alcoholic fatty liver disease (NAFLD) is a common long-lasting that affects millions of people around the world. It best identified with hepatic fat build-up ultimately leads to inflammation and damage. The classification nomenclature NAFLD have long been controversial topic, until 2020 when group international experts recommended substituting MAFLD (metabolic dysfunction-associated FLD). was then terminologically complemented in 2023 by altering it MASLD, i.e., metabolic steatotic (MASLD). Both MASLD terminologies comprise element disorder, as they offer diagnostic benchmarks are embedded risk factors underlie disease. (as multisystemic disease) provides comprehensive definition includes larger population patients who at morbidity mortality, well adverse cardiovascular diabetes outcomes. highlights risks lean or normal weight individuals, factor has not accentuated discussed previous guidelines. Novel antihyperglycemic agents, anti-hyperlipidemic drugs, lifestyle modifications, nutritional interventions, exercise therapies extensively studied MASLD. Nutrition plays vital role managing both conditions, where centralizing on diet rich whole vegetables, fruits, foods, healthy fats, proteins, specific nutrients (e.g., omega-3 acids fibers) can improve insulin resistance reduce inflammation. Thus, essential understand nutrition these conditions work develop an individualized plan for optimal health. This review discusses prevention strategies NAFLD/MAFLD/MASLD management, particular attention correction.

Language: Английский

---

Nutritional Strategies for Battling Obesity-Linked Liver Disease: the Role of Medical Nutritional Therapy in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management

Current Obesity Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Jan. 11, 2025

This narrative review explores the role of Medical Nutritional Therapy (MNT) in managing Metabolic-Associated Steatotic Liver Disease (MASLD), previously known as nonalcoholic fatty liver disease. It aims to examine effectiveness specific nutritional strategies preventing and treating this obesity-linked Emerging evidence underscores benefits Mediterranean diet, low-carbohydrate diets, intermittent fasting reducing fat, improving insulin sensitivity, mitigating inflammation. Supplementing with vitamin E, omega-3 acids, silymarin can potentially reduce fibrosis promote health. MNT is a key intervention for MASLD management, emphasizing dietary patterns, caloric restriction, nutraceutical supplementation. Integrating these lifestyle modifications, including regular physical activity, offers comprehensive approach metabolic outcomes patients MASLD. Further research needed refine personalize therapeutic interventions.

Language: Английский

---

Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 18, 2025

ABSTRACT Background The continuum of metabolic syndrome encompasses a spectrum dysfunctions impacting obesity‐linked insulin resistance, glucose homeostasis, lipid metabolism and pro‐inflammatory immune responses. global prevalence diseases, including diabetes, chronic liver disease, cardiometabolic disease kidney has surged in recent decades, contributing significantly to population mortality. Metabolic dysfunction‐associated steatotic (MASLD), formerly known as non‐alcoholic fatty is leading cause worldwide. MASLD poses significant health challenge with its rising prevalence, placing substantial burden on healthcare systems, impacts patient well‐being incurs economic costs. Addressing requires comprehensive understanding interconnected factors, implications. Lack awareness, imprecise non‐invasive diagnostic methods ineffective preventive interventions are core components the MASLD‐related problem. Aim aim this article was summarise from payer's perspective. Methods We carried out review MASLD. These topics led discussions insights by an expert panel during 7th Continuum Roundtable meeting, which took place November 2023. This meeting focused burden, patient‐reported outcomes economics, payor societal perspectives, aimed identify opportunities for improving care, optimise resource allocation mitigate overall impact individuals society related During roundtable, emphasis emerged need greater awareness strategic deployment diagnostic, therapeutic preventative measures address effectively. Conclusion high growing. Prioritising prevention dysregulation timely can yield holistic strategy combat MASLD, progression potentially lower Trial Registration: NCT06309992

Language: Английский

---

Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?

Diagnostics, Journal Year: 2025, Volume and Issue: 15(3), P. 252 - 252

Published: Jan. 22, 2025

In recent years, novel findings have progressively and promisingly supported the potential role of Artificial intelligence (AI) in transforming management various neoplasms, including hepatocellular carcinoma (HCC). HCC represents most common primary liver cancer. Alarmingly, incidence is dramatically increasing worldwide due to simultaneous “pandemic” spreading metabolic dysfunction-associated steatotic disease (MASLD). MASLD currently constitutes leading cause chronic hepatic damage (steatosis steatohepatitis), fibrosis, cirrhosis, configuring a scenario where an onset has been reported even early stage. On other hand, serious plague, significantly burdening outcomes hepatitis B (HBV) C (HCV) virus-infected patients. Despite progress this cancer, overall prognosis for advanced-stage patients continues be poor, suggesting absolute need develop personalized healthcare strategies further. “cold war”, machine learning techniques neural networks are emerging as weapons, able identify patterns biomarkers that would normally escaped human observation. Using advanced algorithms, AI can analyze large volumes clinical data medical images (including routinely obtained ultrasound data) with elevated accuracy, facilitating diagnosis, improving performance predictive models, supporting multidisciplinary (oncologist, gastroenterologist, surgeon, radiologist) team opting best “tailored” individual treatment. Additionally, contribute enhancing effectiveness metabolomics–radiomics-based promoting identification specific HCC-pathogenetic molecules new targets realizing therapeutic regimens. era precision medicine, integrating into routine practice appears promising frontier, opening avenues cancer research

Language: Английский

---

Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Medicina, Journal Year: 2025, Volume and Issue: 61(2), P. 192 - 192

Published: Jan. 22, 2025

The purpose of this article is to present selected food additives as disruptors normal intestinal homeostasis with a potential impact on the development metabolic dysfunction-associated steatotic liver disease (MASLD). A comprehensive literature search was conducted in three major electronic databases: PubMed, ScienceDirect, and Google Scholar. MASLD prevalent condition that closely related global rise obesity. Its pathogenesis multifactorial, genetic, environmental, factors playing key role. “multiple-hit” hypothesis suggests Western-style diet, rich ultra-processed foods, saturated fats, additives, combined low physical activity, contributes obesity, which promotes lipid accumulation liver. Recent studies underscore role impaired MASLD. Food including preservatives, emulsifiers, sweeteners, affect gut health function. Selected preservatives inhibit pathogenic microorganisms but disrupt microbiota, leading changes permeability dysfunction. Some emulsifiers thickeners can cause inflammation alter microbiome, contributing steatosis. Furthermore, use sweeteners such sucralose aspartame has been linked metabolism microbial composition, turn disorders.

Language: Английский

---

Mitigating Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Role of Bioactive Phytoconstituents in Indian Culinary Spices

Current Nutrition Reports, Journal Year: 2025, Volume and Issue: 14(1)

Published: Jan. 22, 2025

Language: Английский

---